10 Best Treatments for Migraine in 2026

Migraine affects an estimated 12 to 15 percent of adults in the United States, making it one of the most prevalent neurological conditions. For people living with chronic migraine, defined as 15 or more headache days per month for at least 3 months, finding an effective treatment plan often means trying multiple approaches before landing on a combination that works.

The treatment landscape has shifted in recent years. Behavioral programs now target the neuroplastic mechanisms that keep migraine cycles active. CGRP-targeted medications block a peptide directly involved in migraine pain signaling. Neuromodulation devices offer drug-free alternatives with FDA clearance. And the 2026 AAN/AHS guideline now recommends preventive treatment for any adult averaging 4 or more migraine days per month. This guide covers 10 evidence-supported treatment categories to help you and your clinician evaluate what may work for your situation.

Key Takeaways

• Behavioral therapies such as CBT and biofeedback reduce migraine frequency in adults and can be used alongside any medication, with essentially no side effects.
• CGRP-targeted medications, both injectable and oral, are the first preventive drug class designed specifically for migraine and have strong evidence for reducing monthly migraine days.
• The 2026 AAN/AHS guideline recommends preventive treatment for adults with 4 or more migraine days per month or significant migraine-related disability.
• Neuromodulation devices like Cefaly and gammaCore offer drug-free, FDA-cleared options for both prevention and acute treatment.
• A multimodal plan that combines behavioral strategies with pharmacologic or device-based treatments may provide the broadest benefit for people with chronic migraine.

1. Coach-Led Behavioral Migraine Therapy

For people living with chronic or frequent migraine, behavioral therapy targets the neural pathways that keep the pain cycle active rather than masking individual attacks with medication. The approach draws on cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), somatic tracking, and structured coaching to address fear-avoidance behaviors, emotional reactivity to pain, and the thought loops that can amplify migraine frequency over time.

Multicomponent behavioral interventions, including CBT, relaxation training, and mindfulness-based therapies, reduce headache frequency in adults with migraine, based on a systematic review of 50 randomized trials covering 6,024 participants. CBT trials specifically documented a 32% frequency reduction compared to 5% in control groups. Acceptance and commitment therapy reduces headache-related disability at 3-, 6-, and 12-month follow-up in adults with primary headache disorders, including migraine.

What makes behavioral therapy particularly relevant for chronic migraine is its focus on central sensitization, the process by which the nervous system amplifies pain signals even when no new tissue damage exists. In adults with frequent migraine, the brain's pain alarm can become stuck in a heightened state, firing without a proportional trigger. Behavioral approaches work by interrupting fear-avoidance cycles, reducing the emotional charge around attacks, and retraining the brain's response to migraine triggers.

What to expect

Sessions are typically weekly, delivered by a trained recovery coach or therapist. Programs like Lin Health pair live one-on-one coaching with an app for between-session practice, covering behavioral therapy techniques. Side effects are essentially nonexistent, and behavioral therapy can be layered on top of any pharmacologic treatment without interaction concerns.

Who it may help most

Adults with chronic migraine who have tried medications without sufficient relief. People who prefer to reduce medication use or who experience significant side effects from preventive drugs. Anyone dealing with migraine-related anxiety, sleep disruption, or avoidance behaviors that limit daily activity.

2. CGRP Monoclonal Antibodies

Calcitonin gene-related peptide (CGRP) plays a central role in migraine pathophysiology, driving inflammation and pain signaling in the trigeminovascular system. Four monoclonal antibodies now target this pathway: erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti). The first three are self-administered monthly subcutaneous injections. Eptinezumab is given as a quarterly intravenous infusion.

A head-to-head comparison of all four CGRP antibodies found that galcanezumab showed the highest efficacy in reducing monthly migraine days in episodic migraine, while fremanezumab offered the strongest balance of efficacy and safety. Long-term studies confirm sustained long-term efficacy across all four antibodies, with quality-of-life improvements maintained over multiple years of treatment.

The 2026 AAN/AHS guideline supports CGRP monoclonal antibodies as a treatment option for adults meeting criteria for preventive therapy. Common side effects include injection-site reactions and constipation, both generally mild.

Who it may help most

Adults with episodic migraine (4 to 14 migraine days per month) or chronic migraine who have not responded adequately to traditional oral preventives, or who prefer a once-monthly injection over daily pills.

3. Oral CGRP Antagonists (Gepants)

Gepants are small-molecule CGRP receptor antagonists taken as oral tablets. Three are currently available: rimegepant (Nurtec ODT), ubrogepant (Ubrelvy), and atogepant (Qulipta). Rimegepant has FDA approval for both acute treatment and prevention, making it the first migraine medication approved for dual use.

In preventive trials, atogepant reduced monthly migraine days by 0.7 to 2.4 days compared to placebo, with improvements in quality-of-life scores. Rimegepant, taken every other day, achieved prevention within one week of dosing. For acute treatment, a single dose of rimegepant provided complete pain relief at 2 hours in approximately 31% to 33% of patients compared to 15% with placebo.

Side effects are primarily gastrointestinal (constipation, nausea), generally mild to moderate, with no signal of liver or cardiovascular toxicity in clinical trial data.

Who it may help most

Adults who prefer oral medication over injections. People who want a single agent that can serve as both a preventive and an acute rescue treatment (rimegepant). Those with cardiovascular risk factors that make triptans inappropriate.

4. Botulinum Toxin (Botox) for Chronic Migraine

OnabotulinumtoxinA (Botox) is FDA-approved specifically for chronic migraine in adults with 15 or more headache days per month. It is administered as a series of 31 injections across 7 muscle areas of the head and neck every 12 weeks.

Botox reduces headache days with a 50% response rate of approximately 47% at 24 weeks, based on a pooled analysis of 10 years of real-world data, with improvements maintained through 52 weeks. A 5-year retrospective study across 19 headache clinics confirmed a sustained therapeutic effect and favorable safety profile with long-term use.

The most common side effects are neck pain and localized muscle weakness at injection sites, both typically mild and temporary.

Who it may help most

Adults with confirmed chronic migraine (15+ headache days/month) who have not responded adequately to two or more oral preventive medications. Botox is not indicated for episodic migraine with fewer than 15 headache days per month.

5. Neuromodulation Devices

Neuromodulation devices deliver electrical or magnetic stimulation to nerves involved in migraine pathways, offering a drug-free treatment option. Three FDA-cleared devices are widely available:

• Cefaly (external trigeminal nerve stimulation): worn on the forehead, available for both acute treatment and prevention. In clinical trials, compliant users experienced a 32.7% fewer headache days after 3 months, and responders reduced acute medication use by 74.4%.
• gammaCore (non-invasive vagus nerve stimulation): a handheld device applied to the neck, primarily studied for cluster headache but also used for migraine.
• SpringTMS (single-pulse transcranial magnetic stimulation): a handheld device held against the back of the head, shown to stop migraine with aura in roughly 40% of patients within two pulses.

In 2024, Veterans Health Administration providers prescribed over 21,500 neuromodulation devices for migraine, with Cefaly accounting for 53% of orders. Side effects are minimal and typically limited to skin irritation at the stimulation site.

Who it may help most

Adults who want to reduce medication use, cannot tolerate medication side effects, or are pregnant or planning pregnancy. Neuromodulation can also supplement pharmacologic treatment for additional benefit.

6. Triptans

Triptans remain the most widely prescribed class of acute migraine medication. They work by activating serotonin (5-HT1B/1D) receptors to constrict dilated blood vessels and reduce inflammation in the trigeminovascular system. Seven triptans are available: sumatriptan, eletriptan, rizatriptan, zolmitriptan, naratriptan, almotriptan, and frovatriptan.

Triptans outperformed newer acute medications (lasmiditan, rimegepant, ubrogepant) for immediate pain relief and reduced need for rescue medication in a comparative analysis. Among triptans, eletriptan led in two-hour relief, followed by rizatriptan, sumatriptan, and zolmitriptan.

Common side effects include chest tightness, tingling, flushing, and fatigue. Triptans are contraindicated in people with uncontrolled hypertension, coronary artery disease, or a history of stroke due to their vasoconstrictive effects.

Who it may help most

Adults with episodic migraine who need reliable acute relief and have no cardiovascular contraindications. Triptans work most effectively when taken early in an attack, before pain becomes severe.

7. Ditans (Lasmiditan)

Lasmiditan (Reyvow) is the first and only FDA-approved ditan, a selective 5-HT1F receptor agonist. Unlike triptans, it does not cause vasoconstriction, making it a viable acute treatment option for people with cardiovascular risk factors who cannot safely use triptans.

In clinical trials, lasmiditan was more effective than placebo for pain-free status and most bothersome symptom resolution at 2 hours. Real-world data confirm its clinical effectiveness, with tolerability rated as good to excellent by approximately 52% of patients. Effectiveness was not associated with previous triptan failure, meaning it may work even in people who have not responded to triptans.

The primary side effect is dizziness (affecting roughly 15% of patients). Lasmiditan is classified as a Schedule V controlled substance due to low abuse potential. Patients should not drive within 8 hours of taking it.

Who it may help most

Adults with migraine who have cardiovascular contraindications to triptans, those who have not responded to triptans, or those who experience intolerable triptan side effects.

8. Preventive Oral Medications

Before CGRP-targeted therapies arrived, several classes of oral medication were used off-label for migraine prevention. These remain a widely available and lower-cost first-line option in many clinical settings:

• Beta-blockers (propranolol, metoprolol): reduce migraine frequency, particularly in adults with co-occurring hypertension or anxiety.
• Antiepileptics (topiramate, valproate): topiramate is one of the most studied migraine preventives, with evidence for reducing monthly migraine days in adults with episodic and chronic migraine. Weight loss is a common side effect. Valproate carries teratogenic risk and is not recommended for people who may become pregnant.
• Antidepressants (amitriptyline, venlafaxine): amitriptyline (a tricyclic) is commonly used when migraine coexists with tension-type headache, insomnia, or depression.
• ARBs (candesartan): an option for adults with co-occurring hypertension.

The 2026 AAN/AHS guideline addresses how to select among these agents based on patient comorbidities, side-effect profiles, and prior treatment responses. Response should be assessed after 2 to 3 months at adequate dosing before concluding a medication has failed.

Who it may help most

Adults with episodic or chronic migraine who have co-occurring conditions (hypertension, depression, insomnia) that a single medication might address simultaneously. Also a reasonable first option when CGRP-targeted therapies are unavailable due to insurance coverage or cost.

9. Biofeedback and Relaxation Training

Biofeedback uses real-time physiological monitoring (muscle tension, skin temperature, heart rate variability) to teach voluntary control over stress responses that can trigger or intensify migraine. Relaxation training, including progressive muscle relaxation and guided breathing, is often paired with biofeedback for additive benefit.

Biofeedback reduces migraine frequency with a medium-to-large effect size, based on a pooled analysis of 55 studies, with effects maintained at follow-up. The largest benefit appeared when biofeedback was combined with relaxation training. When compared head-to-head with pharmacotherapy, biofeedback showed comparable effectiveness, suggesting it can serve as a standalone option or a complement to medication.

Biofeedback has no pharmacological side effects. Sessions can be conducted in person or, increasingly, through telehealth and wearable-device platforms.

Who it may help most

Adults who experience stress-triggered migraine, those interested in developing long-term self-regulation skills, and people seeking a non-pharmacologic treatment they can practice independently after initial training. Biofeedback also works well as an addition to behavioral programs like mind-body pain therapy.

10. Lifestyle and Integrative Approaches

Lifestyle modifications are foundational to any migraine treatment plan. While they rarely eliminate migraine on their own, they reduce attack frequency and can amplify the effectiveness of other treatments.

• Aerobic exercise: Moderate-quality evidence shows that aerobic exercise reduces migraine frequency in adults, with an average reduction of 0.6 days per month. High-intensity exercise was comparable to or slightly more effective than moderate-intensity in recent trials.
• Sleep regulation: Inconsistent sleep is one of the most commonly reported migraine triggers. Maintaining a consistent wake time and sleep schedule, even on weekends, can reduce attack frequency.
• Magnesium supplementation: Oral magnesium (400 to 600 mg daily of magnesium oxide or citrate) has evidence supporting its use for migraine prevention, particularly in adults with documented magnesium deficiency.
• Riboflavin (vitamin B2): At doses of 400 mg daily, riboflavin has shown reduced migraine frequency in some adults, with minimal side effects.
• Trigger identification: Keeping a pain diary to track patterns between attacks, sleep, meals, stress, and weather can help identify modifiable factors.

Who it may help most

All adults with migraine, regardless of type or frequency. Lifestyle approaches are especially valuable as a baseline for people just beginning treatment and for those adding non-pharmacologic strategies to an existing medication regimen.

How Lin Health Helps with Chronic Migraine

Chronic migraine often involves more than isolated attacks. For many people, the pain cycle becomes self-reinforcing: attacks trigger anxiety, anxiety disrupts sleep, poor sleep lowers the threshold for the next attack, and avoidance behaviors shrink daily life. Lin Health's program is designed to interrupt this cycle by targeting the brain-based mechanisms that keep migraine patterns active.

Lin Health's approach is based on findings from neuroplastic pain research, applying behavioral retraining techniques (CBT, ACT, somatic tracking) through one-on-one sessions with trained recovery coaches. Each session builds skills for managing migraine triggers, reducing the fear and emotional charge around attacks, and breaking the thought loops that amplify pain. Between sessions, a companion app provides structured practice and educational content, including imaginal exposure for migraines.

The program is covered by insurance through major carriers in Colorado, Texas, Florida, California, and New York, with coverage expanding. There is no out-of-pocket cost for eligible patients. Wait times are short, with most patients receiving a same-day callback after sign-up.

Learn more about Lin Health's chronic migraine program, read about chronic migraine prevention, or explore patient recovery stories.

If medications have not provided enough relief on their own, or if migraine-related anxiety and avoidance are limiting your daily life, a behavioral approach may be worth exploring. Check your insurance eligibility. Most patients pay zero out of pocket, and callbacks are typically same-day.

FAQ

What is the most effective treatment for chronic migraine?

There is no single most effective treatment. The 2026 AAN/AHS guideline recommends tailoring prevention to the individual. CGRP-targeted medications and behavioral therapies both have strong trial support, and combining approaches often produces broader results than any single treatment alone.

Can migraine be treated without medication?

Yes. Behavioral therapies (CBT, biofeedback, ACT), neuromodulation devices (Cefaly, gammaCore), and lifestyle changes (aerobic exercise, sleep regulation, stress management) all have clinical evidence supporting their use for migraine prevention.

What are CGRP inhibitors and how do they work for migraine?

CGRP inhibitors block calcitonin gene-related peptide, a protein involved in migraine pain signaling. They come as monthly injections (erenumab, fremanezumab, galcanezumab) or daily oral tablets (atogepant, rimegepant). Trials show they reduce monthly migraine days in adults with episodic and chronic migraine.

Is behavioral therapy effective for migraine?

A 2025 systematic review of 50 randomized trials covering 6,024 adults found that behavioral interventions reduced migraine frequency. CBT trials specifically documented a 32% reduction in headache frequency compared to 5% in controls. These approaches have no pharmacological side effects.

How do I know if I need preventive migraine treatment?

The 2026 AAN/AHS guideline recommends preventive treatment for adults averaging 4 or more migraine days per month, 4 or more moderate-to-severe headache days per month, or migraine-related disability that interferes with daily functioning.

Are migraine treatments covered by insurance?

Coverage varies by plan. CGRP medications often require prior authorization. Behavioral programs like Lin Health are covered by major insurers in Colorado, Texas, Florida, California, and New York. Triptans and traditional preventives are broadly covered. Check with your plan for specifics.

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment for migraine.